Product Banner

World Sexually Transmitted Diseases (STDs) Testing Market - Opportunities and Forecasts, 2013 - 2020

World Sexually Transmitted Diseases (STDs) Testing Market - Opportunities and Forecasts, 2013 - 2020
$4,515.00
$4,515.00
  • Oct 11, 2014
  • 110 pages
  • Allied Market Research
Abstract
Sexually Transmitted Diseases (STDs) are also known as Venereal diseases (VDs) or Sexually Transmitted Infections (STIs). A variety of methods have been employed for diagnosis of STDs that differ based on the type of disease. The objective of this report is to provide an in-depth understanding of diagnostic tests of STDs. The market diagnostic testing of STDs was valued at $96.7 billion in 2013 with a corresponding test volume of 4,204 million. Rising incidences of fatal STDs, corresponding high-economic burden and consequent implementation of Provider-Initiated Counselling and Testing (PICT) and Client-Initiated Counselling and Testing (CICT) drive the growth of STD testing market; however, inadequate infrastructure provisions such as labs, equipment and supplies, lack of trained laboratory personnel in the secluded geographic locations (for example, West African countries) and stigma associated with voluntary testing are likely to be the major restraints of the market. However, global initiatives along with development in healthcare infrastructure will provide future growth thrust for the market. Thus, the diagnostic testing of STDs is estimated to grow at a CAGR of 8.5% over the forecast period 2014-2020 to reach market size of $167.4 billion in 2020. The test volume will rise to 5,520 million in 2020.

The global market for diagnostic testing of STDs is segmented based on types of STDs – Chlamydia testing, Gonorrhoea testing, Syphilis testing, Human Immunodeficiency Virus (HIV) testing, Herpes Simplex Virus (HSV) testing, Human Papilloma Virus (HPV) testing and Chancroid testing. HIV testing, which is the third largest STD testing market, would grow at a CAGR of 10.9% during 2014 – 2020.

Based on point of testing, market is segmented in to laboratories and point-of-care (PoC). Currently, laboratories perform bulk of the tests and would continue to hold larger share of the market, both in terms of volume and revenue. PoCs will grow at constant rate during the forecast period.

The report also provides market size and forecast for testing devices used for carrying such tests. The market for STD testing devices was valued at $7.7 billion in 2013 with laboratory testing devices accounted for the most of the market and PoC devices shall grow at fastest rate.

As elaborated earlier, many healthcare institutions provide diagnostic testing services for STDs, such as specialized STD clinics, Genito-Urinary Medicine (GUM) clinics along with general hospitals, government laboratories and private diagnostic centres. The afore-mentioned thus constitute key market participants of the global diagnostic testing of STDs market. Along with the testing service providers, many companies provide devices such as laboratory instruments and POC testing kits/devices for STDs; for instance, Roche Holdings AG. Roche Holdings AG recently announced an immunoassay diagnostic test for the detection of Syphilis during a routine clinical practice. Other companies profiled in the report are BioMerieux, Hologic Inc., Becton Dickinson & Company, Cepheid Inc., Danaher Corporation, Affymetrix, Alere Inc., Abbott Laboratories, Bio-Rad Laboratories Inc., and DiaSorin.

Global Sexually Transmitted Diseases_01.jpg

KEY BENEFITS

The analysis helps in understanding the strategies adopted by various companies for gaining market share in the market for diagnostic testing of STDs
The report provides comprehensive analysis of factors that drive and restrict the growth of the market for diagnostic testing of STDs.
Market conditions of STD diagnostic testing market across all geographic regions are comprehensively analyzed. Key trends such as national and voluntary screening programs within regional markets, for example, European markets are expected to drive growth of the market.
Prime focus of the report is opportunity-analysis within this market. STD infected individuals refrain from testing in specialized STD clinics and Genito-Urinary Medicine (GUM) clinics due to the associated social stigma. Such change in the consumer buying behavior would prove to be an opportunity and be beneficial for public and private labs.
MARKET SEGMENTATIONThe diagnostic testing of STDs market is segmented into types of STDs tested, testing devices, laboratory testing, PoC testing and geography.

MARKET BY SEXUALLY TRANSMITTED DISEASE TYPES

Chlamydia testing
Syphilis testing
Gonorrhoea testing
Herpes Simplex Virus testing
Human Papilloma Virus testing
Human Immunodeficiency Virus testing
Chancroid testing
MARKET BY LOCATION OF TESTING

Laboratory Testing
Commercial/Private labs
Public Health Labs
Point of Care (PoC) testing
MARKET BY TESTING DEVICES

Laboratory Devices: Instruments and systems
Thermal Cyclers - PCR
Lateral Flow Readers - Immunochromatographic assays
Flow Cytometers
Differential Light Scattering machines
Absorbance microplate reader - Enzyme Linked Immunosorbent Assay (ELISA)
POC testing Devices: Various diagnostic kits
Phone chips (microfluidics + ICT)
Portable / bench top / rapid diagnostic kits
MARKET BY GEOGRAPHY

North America
Europe
Asia-Pacific
Latin America, Middle East, Africa (LAMEA)
Table of Contents
Chapter: 1 INTRODUCTION
1.1 Report description
1.2 Key benefits
1.3 Key market segments
1.4 Research methodology

1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models



$0(SU)
Chapter: 2 EXECUTIVE SUMMARY
2.1 CXO perspective
2.2 Market beyond what to expect by 2025 ($ Million)

2.2.1 Base case scenario
2.2.2 Optimistic scenario
2.2.3 Critical scenario



$195(SU)
Chapter: 3 MARKET OVERVIEW
3.1 Market Definition and Scope
3.2 Upcoming trends for STDs diagnostic testing market
3.3 Technological Advancements for STDs diagnostic testing market
3.4 Emerging economies as a beneficial criterion for the investors

3.4.1 Top Factors Impacting for STDs diagnostic testing market
3.4.3 Top winning strategies for STDs diagnostic testing market

3.5 Different types of diagnostic tests of STDs
3.6 Government Regulations and reimbursement

3.6.1 California codes with different Laws related to STD control
3.6.2 Reimbursement policies for STD testing

3.7 Value chain analysis of STD testing devices market

3.7.1 Source: AMR Analysis Primary Activities
3.7.2 Supportive Activities

3.8 Market Dynamics

3.8.1 Drivers

3.8.1.1 Growing incidence rates and increasing prevalence rates of STD
3.8.1.2 Implementation of National Screening Programs
3.8.1.3 Supporting Reimbursement for STDs testing

3.8.2 Restraints

3.8.2.1 Social stigma associated with patients visiting specialized STD clinics.
3.8.2.2 Huge proportion of patients infected with STDs in out-of-reach geographic areas.
3.8.2.3 Stringent regulatory abidance requirements for the participants of std market

3.8.3 Opportunities

3.8.3.1 Decreasing number of visits to GUM clinics and specialized STD clinics
3.8.3.2 National screening Programs across the globe
3.8.3.3 Niche opportunities for technology and POC test providers in an emerging economies



$595(SU)
Chapter: 4 GLOBAL STDS DIAGNOSTIC TESTING MARKET BY DISEASE TYPE
4.1 Chlamydia testing (volume and value)

4.1.1 Key market trends
4.1.2 Market size and forecast

4.1.2.1 Global Testing Market for Chlamydia, volume
4.1.2.2 Global Testing Market for Chlamydia, Value

4.2 P&S Syphilis testing (volume and value)

4.2.1 Key market trends
4.2.2 Market size and forecast

4.2.2.1 Global Testing Market for P&S Syphilis, volume
4.2.2.2 Global Testing Market for P&S Syphilis,value

4.2.3 Global P&S syphilis testing market, by Region

4.2.3.1 Europe

4.2.3.1.1 SPAIN
4.2.3.1.2 GREECE

4.2.3.2 All Other Europe
4.2.3.3 LAMEA

4.2.3.3.1 LATIN AMERICA
4.2.3.3.2 ARGENTINA
4.2.3.3.3 MIDDLE EAST
4.2.3.3.4 AFRICA

4.2.4 Global P&S Syphilis testing Market, By Type

4.2.4.1 Primary Syphilis
4.2.4.2 Secondary Syphilis

4.3 Gonorrhea testing (volume and value)

4.3.1 Key market trends
4.3.2 Market size and forecast

4.3.2.1 Global Testing Market for Gonorrhea,volume
4.3.2.2 Global Testing Market for Gonorrhea,value

4.4 Herpes Simplex Virus (HSV) testing (volume and value)

4.4.1 Key market trends
4.4.2 Market size and forecast

4.4.2.1 Global Testing Market for HSV,volume
4.4.2.2 Global Testing Market for HSV,value

4.5 Human Papilloma Virus (HPV) testing (volume and value)

4.5.1 Key market trends
4.5.2 Market size and forecast

4.5.2.1 Global Testing Market for HPV,volume
4.5.2.2 Global Testing Market for HPV,value

4.6 Human Immunodeficiency Virus (HIV) testing (volume and value)

4.6.1 Key market trends
4.6.2 Market size and forecast

4.6.2.1 Global Testing Market for HiV,volume
4.6.2.2 Global Testing Market for HiV,value

4.7 Chancroid testing (volume and value)

4.7.1 Key market trends
4.7.2 Market size and forecast

4.7.2.1 Global Testing Market for Chancroid,volume
4.7.2.2 Global Testing Market for Chancroid,value



$895(SU)
Chapter: 5 GLOBAL STDS DIAGNOSTIC TESTING MARKET BY LOCATION OF TESTING
5.1 Market size and forecast
5.2 Laboratory testing

5.2.1 Key market trends
5.2.2 Key growth factors and opportunities
5.2.3 Commercial laboratory testing
5.2.4 Private laboratory testing
5.2.5 Public laboratory testing
5.2.6 Key market trends
5.2.7 Key growth factors and opportunities



$995(SU)
Chapter: 6 GLOBAL STDS DIAGNOSTIC TESTING MARKET BY TESTING DEVICES
6.1 Market size and forecast
6.2 Laboratory Testing Devices

6.2.1 PCRs
6.2.2 Immunochromatographic capillary flow dipstick technology (Assay)
6.2.3 Flow Cytometers
6.2.4 Differential Light Scattering
6.2.5 Enzyme Linked Immunosorbent Assay (ELISA)

6.3 Point of Care Testing Devices

6.3.1 Phone Chips
6.3.2 Microfluidics
6.3.3 Immunochromatographic Tests (ICTs)
6.3.4 Rapid diagnostic kits



$995(SU)
Chapter: 7 GLOBAL STDS DIAGNOSTIC TESTING MARKET BY GEOGRAPHY
7.1 North America
7.2 Europe
7.3 Asia Pacific
7.4 LAMEA

7.4.1 LAMEA STD testing market by disease type (value and Volume), 2013-2020

7.4.1.1 LAMEA Chlamydia testing market by region, (volume & value), 2013-2020

7.4.1.1.1 LATIN AMERICA
7.4.1.1.2 MIDDLE EAST
7.4.1.1.3 SOUTH AFRICA
7.4.1.1.4 OTHER AFRICAN COUNTRIES

7.4.1.2 LAMEA P&S Syphilis testing market by region, (volume & value), 2013-2020

7.4.1.2.1 LATIN AMERICA
7.4.1.2.2 MIDDLE EAST
7.4.1.2.3 SOUTH AFRICA
7.4.1.2.4 OTHER AFRICAN COUNTRIES

7.4.1.3 LAMEA Gonorrhea testing market by region, (volume & value), 2013-2020

7.4.1.3.1 LATIN AMERICA
7.4.1.3.2 MIDDLE EAST
7.4.1.3.3 SOUTH AFRICA
7.4.1.3.4 OTHER AFRICAN COUNTRIES

7.4.1.4 LAMEA Herpes Simplex Virus testing market by region, (volume & value), 2013-2020

7.4.1.4.1 LATIN AMERICA
7.4.1.4.2 MIDDLE EAST
7.4.1.4.3 SOUTH AFRICA
7.4.1.4.4 OTHER AFRICAN COUNTRIES

7.4.1.5 LAMEA Human Papilloma Virus testing market by region, (volume & value), 2013-2020

7.4.1.5.1 LATIN AMERICA
7.4.1.5.2 MIDDLE EAST
7.4.1.5.3 SOUTH AFRICA
7.4.1.5.4 OTHER AFRICAN COUNTRIES

7.4.1.6 LAMEA Human Immunodeficiency Virus testing market by region, (volume & value), 2013-2020

7.4.1.6.1 LATIN AMERICA
7.4.1.6.2 MIDDLE EAST
7.4.1.6.3 SOUTH AFRICA
7.4.1.6.4 OTHER AFRICAN COUNTRIES

7.4.1.7 LAMEA Chancroid testing market by region, (volume & value), 2013-2020

7.4.1.7.1 LATIN AMERICA
7.4.1.7.2 MIDDLE EAST
7.4.1.7.3 SOUTH AFRICA
7.4.1.7.4 OTHER AFRICAN COUNTRIES



$895(SU)
Chapter: 8 COMPANY PROFILES
8.1 Roche Diagnostics

8.1.1 Company overview
8.1.2 Operating business segments
8.1.3 Financial performance
8.1.4 Strategic moves and developments
8.1.5 SWOT analysis Roche Diagnostics

8.2 Biomerieux

8.2.1 Company overview
8.2.2 Operating business segments
8.2.3 Business performance
8.2.4 SWOT analysis of BioMerieux

8.3 Hologic, Inc.

8.3.1 Company overview
8.3.2 Operating business segments
8.3.3 Financial performance
8.3.4 Strategic moves and developments
8.3.5 SWOT analysis of Hologic Inc

8.4 Becton Dickinson And Company

8.4.1 Company overview
8.4.2 Operating Business Segments
8.4.3 Business performance
8.4.4 Key Strategies and development
8.4.5 SWOT analysis of Becton Dickinson and Company

8.5 Cepheid Inc.

8.5.1 Company overview
8.5.2 Operating Business Segments
8.5.3 Financial performance
8.5.4 Strategic moves and developments
8.5.5 SWOT analysis of Cepheid’s

8.6 Danaher Corporation

8.6.1 Company overview
8.6.2 Operating business segments
8.6.3 Business performance
8.6.4 Key Strategies and development
8.6.5 SWOT analysis of Danaher Corporation

8.7 Affymetrix, Inc.

8.7.1 Company overview
8.7.2 Operating. business segments
8.7.3 Financial performance
8.7.4 SWOT analysis of Affymetrix Inc

8.8 Alere Inc.

8.8.1 Company overview
8.8.2 Operating business segments
8.8.3 Business performance
8.8.4 Key Strategies and developments
8.8.5 SWOT analysis of Alere Inc.

8.9 Abbott Laboratories

8.9.1 Company overview
8.9.2 Operating business segments
8.9.3 Financial performance
8.9.4 Strategic moves and developments
8.9.5 SWOT analysis of Abbott’s

8.10 DiaSorin

8.10.1 Company overview
8.10.2 Operating business segments
8.10.3 Financial performance
8.10.4 Strategic moves and developments
8.10.5 SWOT analysis of DiaSorin

LIST OF TABLES

TABLE 1 GLOBAL STD DIAGNOSTIC TESTING MARKET, MODERATE GROWTH SCENARIO BY GEOGRAPHY, 2020-2025 ($MILLION)
TABLE 2 GLOBAL STD DIAGNOSTIC TESTING MARKET, RAPID GROWTH SCENARIO BY GEOGRAPHY, 2020-2025 ($MILLION)
TABLE 3 GLOBAL STD DIAGNOSTIC TESTING MARKET, DIMINISHING GROWTH SCENARIO BY GEOGRAPHY, 2020-2025 ($MILLION)
TABLE 4 STD PREVENTIVE SERVICES BY CDC
TABLE 5 GLOBAL STD TESTING MARKET REVENUE, BY DISEASE TYPE, 2013-2020 ($MILLION)
TABLE 6 GLOBAL STD TESTING MARKET VOLUME, BY DISEASE TYPE, 2013-2020 (IN MILLION)
TABLE 7 GLOBAL CHLAMYDIA TESTING MARKET VOLUME, BY GEOGRAPHY, 2013-2020 (IN MILLION)
TABLE 8 GLOBAL CHLAMYDIA TESTING MARKET REVENUE, BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 9 GLOBAL P&S SYPHILIS TESTING MARKET VOLUME, BY GEOGRAPHY, 2013-2020 (IN MILLION)
TABLE 10 GLOBAL P&S SYPHILIS TESTING MARKET REVENUE, BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 11 EUROPE P&S SYPHILIS TESTING MARKET BY VALUE ($MILLION), 2013-2020
TABLE 12 EUROPE P&S SYPHILIS TESTING MARKET BY VOLUME (MILLION), 2013-2020
TABLE 13 SPAIN P&S SYPHILIS TESTING MARKET VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 14 GREECE P&S SYPHILIS TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 15 OTHERS EUROPE P&S SYPHILIS TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 16 LAMEA P&S SYPHILIS TESTING MARKET BY VALUE, ($MILLION), 2013-2020
TABLE 17 LAMEA P&S SYPHILIS TESTING MARKET BY VOLUME (MILLION), 2013-2020
TABLE 18 LATIN AMERICA P&S SYPHILIS TESTING MARKET BY VALUE ($MILLION), 2013-2020
TABLE 19 LATIN AMERICA P&S SYPHILIS TESTING MARKET BY VOLUME (MILLION), 2013-2020
TABLE 20 ARGENTINA P&S SYPHILIS TESTING MARKET , VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 21 MIDDLE EAST P&S SYPHILIS TESTING MARKET VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 22 AFRICA P&S SYPHILIS TESTING MARKET BY VALUE ($MILLION), 2013-2020
TABLE 23 AFRICA P&S SYPHILIS TESTING MARKET BY VOLUME (MILLION), 2013-2020
TABLE 24 GLOBAL P&S SYPHILIS TESTING MARKET BY VALUE ($MILLION), 2013-2020
TABLE 25 GLOBAL P&S SYPHILIS TESTING MARKET BY VOLUME (MILLION), 2013-2020
TABLE 26 PERCENTAGE FOR TOTAL NUMBER OF CASES OF GONORRHEA RESISTANCE (%)
TABLE 27 GLOBAL GONORRHEA TESTING MARKET VOLUME, BY GEOGRAPHY, 2013-2020 (IN MILLION)
TABLE 28 GLOBAL GONORRHEA TESTING MARKET REVENUE, BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 29 GLOBAL HSV TESTING MARKET VOLUME, BY GEOGRAPHY, 2013-2020 (IN MILLION)
TABLE 30 GLOBAL HSV TESTING MARKET REVENUE, BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 31 GLOBAL HPV TESTING MARKET VOLUME, BY GEOGRAPHY, 2013-2020 (IN MILLION)
TABLE 32 GLOBAL HPV TESTING MARKET REVENUE, BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 33 GLOBAL HIV TESTING MARKET VOLUME, BY GEOGRAPHY, 2013-2020 (IN MILLION)
TABLE 34 GLOBAL HIV TESTING MARKET REVENUE, BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 35 GLOBAL CHANCROID TESTING MARKET VOLUME, BY GEOGRAPHY, 2013-2020 (IN MILLION)
TABLE 36 GLOBAL CHANCROID TESTING MARKET REVENUE, BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 37 GLOBAL STDS TESTING MARKET REVENUE, BY LOCATION OF TESTING SERVICES, 2013-2020 ($ MILLION)
TABLE 38 GLOBAL STD DIAGNOSTIC TESTING MARKET BY TESTING DEVICES, 2013-2020, $ MILLION
TABLE 39 TESTING TECHNOLOGIES FOR STDS
TABLE 40 SEROLOGICAL TEST FOR STDS
TABLE 41 GLOBAL STDS DIAGNOSTICS TESTING MARKET, BY GEOGRAPHY, 2013 - 2020 ($ MILLION)
TABLE 42 GLOBAL STDS DIAGNOSTICS TESTING MARKET, BY GEOGRAPHY, 2013 - 2020 ($ MILLION)
TABLE 43 NORTH AMERICA STDS DIAGNOSTICS TESTING MARKET, BY DISEASE TYPE, 2013-2020, ($MILLION)
TABLE 44 EUROPE STDS DIAGNOSTICS TESTING MARKET, BY DISEASE TYPE, 2013-2020, ($MILLION)
TABLE 45 ASIA PACIFIC STDS DIAGNOSTICS TESTING MARKET, BY DISEASE TYPE, 2013-2020, ($MILLION)
TABLE 46 LAMEA STDS DIAGNOSTICS TESTING MARKET, BY DISEASE TYPE, 2013-2020, ($MILLION)
TABLE 47 LAMEA STDS TESTING MARKET BY VOLUME (MILLION), 2013-2020
TABLE 48 LATIN AMERICA CHLAMYDIA TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 49 MIDDLE EAST CHLAMYDIA TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 50 SOUTH AFRICA CHLAMYDIA TESTING MARKET VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 51 OTHER AFRICAN COUNTRIES CHLAMYDIA TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 52 LATIN AMERICA P&S SYPHILIS TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 53 MIDDLE EAST P&S SYPHILIS TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 54 SOUTH AFRICA P&S SYPHILIS TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 55 OTHER AFRICAN COUNTRIES P&S SYPHILIS TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 56 LATIN AMERICA GONORRHOEA TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 57 MIDDLE EAST GONORRHOEA TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 58 SOUTH AFRICA GONORRHOEA TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 59 OTHER AFRICAN COUNTRIES GONORRHOEA TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 60 LATIN AMERICA HSV TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 61 MIDDLE EAST HSV TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 62 SOUTH AFRICA HSV TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 63 OTHER AFRICAN COUNTRIES HSV TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 64 LATIN AMERICA HPV TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 65 MIDDLE EAST HPV TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 66 SOUTH AFRICA HPV TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 67 OTHER AFRICAN COUNTRIES HPV TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 68 LATIN AMERICA HIV TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 69 MIDDLE EAST HIV TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 70 SOUTH AFRICA HIV TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 71 OTHERS AFRICAN COUNTRIES HIV TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 72 LATIN AMERICA CHANCROID TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 73 MIDDLE EAST CHANCROID TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 74 SOUTH AFRICA CHANCROID TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 75 OTHER AFRICAN COUNTRIES CHANCROID TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 76 ROCHE DIAGNOSTICS COMPANY SNAPSHOT
TABLE 77 ROCHE DIAGNOSTICS OPERATING SEGEMENTS
TABLE 78 BIOMERIEUX COMPANY SNAPSHOT
TABLE 79 BIOMERIEUX OPERATING SEGEMENTS
TABLE 80 HOLOGIC, INC. COMPANY SNAPSHOT
TABLE 81 HOLOGIC, INC. OPERATING SEGEMENTS
TABLE 82 BECTON DICKINSON AND COMPANY SNAPSHOT
TABLE 83 BECTON DICKINSON AND COMPANY OPERATING SEGEMENTS
TABLE 84 CEPHIDE INC COMPANY SNAPSHOT
TABLE 85 CEPHEID INC. OPERATING SEGEMENTS
TABLE 86 DANAHER COMPANY SNAPSHOT
TABLE 87 DANAHER CORPORATION OPERATING SEGEMENTS
TABLE 88 AFFYMETRIX INC. COMPANY SNAPSHOT
TABLE 89 AFFYMETRIX, INC. OPERATING SEGEMENTS
TABLE 90 ALERE INC. COMPANY SNAPSHOT
TABLE 91 ALERE INC. OPERATING SEGEMENTS
TABLE 92 ABBOTT LABORATORIES COMPANY SNAPSHOT
TABLE 93 ABBOTT LABORATORIES OPERATING SEGEMENTS
TABLE 94 DANAHER COMPANY SNAPSHOT
TABLE 95 DIASORIN OPERATING SEGEMENTS

LIST OF FIGURES

FIG. 1 IMPACT ANALYSIS OF MODERATE GROWTH SCENARIO (2020-2025)
FIG. 2 IMFPACT ANALYSIS OF RAPID GROWTH SCENARIO (2020-2025)
FIG. 3 IMPACT ANALYSIS OF DIMINISHING GROWTH SCENARIO (2020-2025)
FIG. 4 TOP FACTORS IMPACTING GLOBAL STD MARKET, 2013-2020
FIG. 5 TOP INVESTMENT POCKETS FOR STDS DIAGNOSTICS MARKET (2013-2020)
FIG. 6 TOP WINING STRATEGIES IN GLOBAL STD TESTING MARKET (2011-2014)
FIG. 7 VALUE CHAIN ANALYSIS OF STD DIAGNOSTIC TESTING MARKET
FIG. 8 KEY FINANCIALS OF ROCHE DIAGNOSTICS BY GEOGRAPHY (2013)
FIG. 9 SWOT ANALYSIS OF ROCHE DIAGNOSTICS
FIG. 10 KEY FINANCIALS OF BIOMERIEUX BY APPLICATIONS (2013)
FIG. 11 KEY FINANCIALS OF BIOMERIEUX BY GEOGRAPHY (2013)
FIG. 12 SWOT ANALYSIS OF BIOMERIEUX
FIG. 13 KEY FINANCIALS OF HOLOGIC, INC. BY OPERATING SEGMENTS (2012)
FIG. 14 KEY FINANCIALS OF HOLOGIC, INC. BY GEOGRAPHY (2012)
FIG. 15 SWOT ANALYSIS OF HOLOGIC, INC.
FIG. 16 KEY FINANCIALS OF BECTON DICKINSON AND COMPANY BY SEGMENT (2013)
FIG. 17 KEY FINANCIALS OF BECTON DICKINSON AND COMPANY BY GEOGRAPHY (2013)
FIG. 18 SWOT ANALYSIS OF BECTON DICKINSON AND COMPANY
FIG. 19 KEY FINANCIALS OF CEPHEID INC. BY GEOGRAPHY (2013)
FIG. 20 KEY FINANCIALS OF CEPHEID INC. BY CLINICAL AND NON CLINICAL MARKET(2013)
FIG. 21 SWOT ANALYSIS OF CEPHEID INC.
FIG. 22 KEY FINANCIALS OF DANAHER CORPORATION BY OPERATING (SEGMENT) 2013
FIG. 23 KEY FINANCIALS OF DANAHER CORPORATION BY GEOGRAPHY (2013)
FIG. 24 SWOT ANALYSIS OF DANAHER CORPORATION
FIG. 25 KEY FINANCIALS OF AFFYMETRIX, INC. BY OPERATING SEGMENTS (2013)
FIG. 26 KEY FINANCIALS OF AFFYMETRIX, INC. BY GEOGRAPHY (2013)
FIG. 27 SWOT ANALYSIS OF AFFYMETRIX INC.
FIG. 28 KEY FINANCIALS OF ALERE INC. BY OPERATING SEGMENTS (2013)
FIG. 29 KEY FINANCIALS OF ALERE INC. BY GEOGRAPHY (2013)
FIG. 30 SWOT ANALYSIS OF ALERE INC.
FIG. 31 KEY FINANCIALS OF ABBOTT LABORATORIES BY OPERATING SEGMENTS (2013)
FIG. 32 SWOT ANALYSIS OF ABBOTT LABORATORIES
FIG. 33 KEY FINANCIALS OF DIASORIN BY TECHNOLOGY (2013)
FIG. 34 KEY FINANCIALS OF DIASORIN BY GEOGRAPHY (2013)
FIG. 35 SWOT ANALYSIS OF DIASORI
List of Figures
List of Tables
Companies Covered